SLC22A5 polyclonal Antibody | BS6733

SLC22A5 polyclonal Antibody | BS6733 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB 1:500 - 1:2000 IHC 1:50 - 1:200

Background: Carnitine (b-hydroxy-g-trimethylaminobutyrate) is a small, highly polar compound that aids in the b-oxidation of long-chain fatty acids. Organic cation/carnitine transporters (OCTN) assist in the elimination of cationic compounds, including xenobiotics, and transport carnitine for reabsorption in the kidney. Similar to organic cation transporters (OCT), OCTN proteins localize to the plasma membrane of epithelial cells. OCTN1 is expressed in kidney, trachea, bone marrow and fetal liver. OCTN2 is abundantly expressed in kidney, skeletal muscle, placenta and heart. OCTN3 is strongly expressed in testis and weakly expressed in kidney. The gene encoding human OCTN1 maps to chromosome 5 and the gene encoding human OCTN2 maps to chromosome 5q31. Mutations in the gene encoding OCTN2 leads to systemic carnitine deficiency (SCD), an autosomal recessive disorder characterized by cardiomyopathy, skeletal myopathy, lethargy, hypoglycemia and hyperammonemia.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: SLC22A5 polyclonal Antibody detects endogenous levels of SLC22A5 protein.

Molecular Weight: ~ 80 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: CDSP; High-affinity sodium-dependent carnitine cotransporter; OCTN2; OCTN2VT; Organic cation/carnitine transporter 2; S22A5; Slc22a5; Solute carrier family 22 (organic cation/carnitine transporter) member 5; Solute carrier family 22 member 5

Immunogen: Recombinant protein of human SLC22A5.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Contribution of ECM and Cytoskeletal Factors to EMT,